Full-Time

Specialist/Senior Specialist

Clinical Data Management

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$80k - $100kAnnually

+ Annual Bonus + Equity

Junior, Mid

New York, NY, USA

On-site requirement of at least three days per week.

Category
Data Management
Data & Analytics

You match the following Axsome Therapeutics Inc's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • Bachelor’s degree required. Preference to candidates with a life science degree
  • At least 2 years’ data management experience in a biotech/pharmaceutical company or clinical research organization (CRO), or clinical research site with Data Management focus or related duties
  • Ability to work on site Monday, Tuesday & Thursday. *We are unable to consider candidates who are looking for fully remote roles*
Responsibilities
  • Support Data Management oversight of multiple clinical development programs
  • Serve as primary liaison for Data Management vendor for assigned studies as well as primary resource for study team and monitors
  • Support the planning and management of data Management timelines
  • Represent Data Management function on the clinical team meetings ensuring aligned expectations between the vendor and Axsome
  • Create and maintain study data cleaning trackers
  • Ensure achievement of major Data Management deliverables and milestones in coordination with other functions including Clinical Operations, Safety, Statistics, etc.
  • Maintain all Data Management documentation to ensure inspection readiness of all Data Management Trial Master File (TMF) documents
  • Draft/review Data Management Plans, data entry guidelines, Data Management reports, validation plans, lab reconciliations and other DM and study specific documents
  • Support the development of Case Report Forms (CRFs) and edit checks per protocol and performs user acceptance testing of CRFs and co-develops associated edit check specifications as required
  • Assist in preparing clean databases by performing reviews of clinical trial data through electronic data capture (EDC) and/or data listings
  • Generate queries, data listings, metrics, quality reports to appropriate internal or external personnel (i.e. investigational sites, vendors, Clinical Research Associates) to assist in overseeing quality and resolve problematic data identified during every aspect of the data management process
  • Review responses to queries for appropriateness and resolution to ensure high data quality
  • Generate custom safety listings and presents to Medical Monitor and study team
  • Gather metrics to support risk-based monitoring
  • Responsible for training of Clinical Trial Associates (CTAs)/Clinical Program Coordinators (CPCs) on data management activities
Desired Qualifications
  • Good understanding of FDA, GCP and ICH guidelines
  • Experience with electronic data capture (EDC) systems/technologies as applied to clinical trials
  • Good working knowledge of (e)CRF design and data management functions/activities
  • Good working knowledge of Microsoft Office software and apps with strong knowledge of Excel. A plus if proficient with data visualizations and database concepts
  • Ability to handle multiple clinical programs simultaneously
  • Comfortable multi-tasking in a fast-paced small company environment and able to adjust workload based upon changing priorities
  • Preference to strong work ethic, energetic candidates with a desire to think “outside the box”
  • Strong attention to detail, time management, and excellent organizational skills
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain to help regulate mood. This drug has shown positive results in clinical trials and has received special FDA status to speed up its approval process. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and development. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
  • Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
  • Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

What critics are saying

  • Increased competition from companies like Compass Pathways in the CNS market.
  • Potential delays in AXS-07 launch amid growing market anticipation.
  • Departure of key personnel like Lori Englebert may impact strategic direction.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 2nd, 2024
PDT Partners LLC Makes New $1.05 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

PDT Partners LLC makes new $1.05 million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Nov 29th, 2024
FORA Capital LLC Makes New $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

FORA Capital LLC makes new $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).